Edgewise Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Edgewise Therapeutics Current Ratio Growth & History (EWTX)
Edgewise Therapeutics's current ratio was 19.85 for fiscal 2025.
View full Edgewise Therapeutics company overviewEdgewise Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 19.85 | −0.07 | −0.38% |
| 2024 | 2024-12-31 | 19.93 | 0.43 | +2.21% |
| 2023 | 2023-12-31 | 19.50 | −2.03 | −9.42% |
| 2022 | 2022-12-31 | 21.53 | −5.45 | −20.19% |
| 2021 | 2021-12-31 | 26.97 | −2.89 | −9.67% |
| 2020 | 2020-12-31 | 29.86 | — | — |
Edgewise Therapeutics quarterly current ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 16.24 | −12.63 | −43.76% |
| Q1 2026 | 2026-03-31 | 22.61 | 1.63 | +7.74% |
| Q4 2025 | 2025-12-31 | 19.85 | −0.07 | −0.38% |
| Q3 2025 | 2025-09-30 | 26.51 | 0.17 | +0.63% |
| Q2 2025 | 2025-06-30 | 28.87 | −1.37 | −4.54% |
| Q1 2025 | 2025-03-31 | 20.99 | −16.10 | −43.40% |
| Q4 2024 | 2024-12-31 | 19.93 | 0.43 | +2.21% |
| Q3 2024 | 2024-09-30 | 26.35 | 8.11 | +44.48% |
| Q2 2024 | 2024-06-30 | 30.24 | 8.23 | +37.38% |
| Q1 2024 | 2024-03-31 | 37.08 | 10.87 | +41.44% |
| Q4 2023 | 2023-12-31 | 19.50 | −2.03 | −9.42% |
| Q3 2023 | 2023-09-30 | 18.23 | −9.59 | −34.46% |
| Q2 2023 | 2023-06-30 | 22.01 | −5.48 | −19.92% |
| Q1 2023 | 2023-03-31 | 26.22 | −0.63 | −2.36% |
| Q4 2022 | 2022-12-31 | 21.53 | −5.45 | −20.19% |
| Q3 2022 | 2022-09-30 | 27.82 | −5.67 | −16.94% |
| Q2 2022 | 2022-06-30 | 27.49 | −17.47 | −38.85% |
| Q1 2022 | 2022-03-31 | 26.85 | −37.17 | −58.06% |
| Q4 2021 | 2021-12-31 | 26.97 | −2.89 | −9.67% |
| Q3 2021 | 2021-09-30 | 33.50 | — | — |
| Q2 2021 | 2021-06-30 | 44.96 | — | — |
| Q1 2021 | 2021-03-31 | 64.02 | — | — |
| Q4 2020 | 2020-12-31 | 29.86 | — | — |
Edgewise Therapeutics current ratio trends
Over the last five fiscal years, Edgewise Therapeutics's current ratio decreased from 29.86 to 19.85, a change of −10.01. The latest reported quarter, Q2 2026, shows 16.24.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Edgewise Therapeutics source filings ↗